Metabolomics : Official journal of the Metabolomic Society · 2025
Exploring the potential relationship between serum biomarkers in obese individuals and cancer using FTIR, metabolomics, and lipidomics.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Marques Maria Eduarda, Silva Natália Ferreira, do Prado Mascarenhas Fernanda Naves Araújo, Tomiosso Tatiana Carla, de Oliveira Júnior Robson José, Rodrigues Ricardo, Almeida-Souza Hebreia Oliveira, Martins Mário Machado, Bastos Luciana Machado, Dos Santos Nossol Arlene Bispo, da Costa Silva Tiara, de Andrade Camila Moreira, Guevara-Vega Marco Fidel, Sabino-Silva Robinson, Ueira-Vieira Carlos, Zanon Renata Graciele
Аннотация
INTRODUCTION: Robust evidence endorsed by the International Agency for Research on Cancer demonstrates that excess body fat represents a risk for the development of at least 13 types of cancer.
OBJECTIVE: We investigated the serum of individuals with obesity who had no history of cancer (either personal or familial) to identify biomarkers.
METHODS: 45 individuals were included in this study; they did not show significant differences regarding age, sex, or physical activity. A quality-of-life questionnaire was administered to all participants, revealing that the obese group self-reported difficulties in functional capacity and a greater association with comorbidities, notably hypertension. FTIR, metabolomic, and lipidomic analyses were performed to identify spectral peaks, metabolic, and lipids differentiating between the NO (non-obese) and OB (obese) groups.
RESULTS: The identified peaks are predominantly associated with profiles of lipids, carbohydrates, and nitrogenous compounds. A total of six metabolites and lipids were identified at different levels in the serum of the OB group that have a direct relationship with the development or metabolism of cancer cells (three metabolites and three lipids). Among these, some suggest a reduced likelihood of cancer development, while others indicate an increased potential for cancer development. In this context, we can highlight two substances: the metabolite 4-Hydroxyphenylglyoxylate, which is reduced in the serum of individuals with obesity, and the lipid Glycidyl palmitate, which is elevated in individuals with obesity.
CONCLUSION: 4-Hydroxyphenylglyoxylate and Glycidyl palmitate can be used as biomarkers for cancer and obesity correlation. New experiments manipulating these substances may contribute to a better understanding of their interactions with cancer cells.
OBJECTIVE: We investigated the serum of individuals with obesity who had no history of cancer (either personal or familial) to identify biomarkers.
METHODS: 45 individuals were included in this study; they did not show significant differences regarding age, sex, or physical activity. A quality-of-life questionnaire was administered to all participants, revealing that the obese group self-reported difficulties in functional capacity and a greater association with comorbidities, notably hypertension. FTIR, metabolomic, and lipidomic analyses were performed to identify spectral peaks, metabolic, and lipids differentiating between the NO (non-obese) and OB (obese) groups.
RESULTS: The identified peaks are predominantly associated with profiles of lipids, carbohydrates, and nitrogenous compounds. A total of six metabolites and lipids were identified at different levels in the serum of the OB group that have a direct relationship with the development or metabolism of cancer cells (three metabolites and three lipids). Among these, some suggest a reduced likelihood of cancer development, while others indicate an increased potential for cancer development. In this context, we can highlight two substances: the metabolite 4-Hydroxyphenylglyoxylate, which is reduced in the serum of individuals with obesity, and the lipid Glycidyl palmitate, which is elevated in individuals with obesity.
CONCLUSION: 4-Hydroxyphenylglyoxylate and Glycidyl palmitate can be used as biomarkers for cancer and obesity correlation. New experiments manipulating these substances may contribute to a better understanding of their interactions with cancer cells.